Recommendations for the ethical conduct of vaccination awareness campaigns by biopharmaceutical companies

References

• The Editors. Vaccine hesitancy: a generation at risk. Lancet Child & Adolesc Health. 2019;3(5):281. doi:10.1016/s2352-4642(19)30092-6.
   PubMedGoogle Scholar
• Larson HJ, Cooper LZ, Eskola J, Katz SL, Ratzan S. Addressing the vaccine confidence gap. Lancet. 2011;378(9790):526–7. doi:10.1016/S0140-6736(11)60678-8.
   PubMed Web of Science ®Google Scholar
• Taylor S, Landry CA, Paluszek MM, Groenewoud R, Rachor GS, Asmundsondoi GJG. A proactive approach for managing COVID-19: the importance of understanding the motivational roots of vaccination hesitancy for SARS-CoV2. Front Psychol. 2020;11:575950. doi:10.3389/fpsyg.2020.575950.
   PubMed Web of Science ®Google Scholar
• European Parliament and the Council of the European Union. Directive 2001/83/EC community code relating to medicinal products for human use. 2001 [Accessed 2020 Oct]. https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/dir_2001_83_consol_2012/dir_2001_83_cons_2012_en.pdf
   Google Scholar
• Bélisle-Pipon J-C, Williams-Jones B. Drug Familiarization and Therapeutic Misconception via direct-to-consumer information. J Bioeth Inq. 2015;12(2):259–67. doi:10.1007/s11673-015-9634-8.
   PubMed Web of Science ®Google Scholar
• Health Canada. The distinction between advertising and other activities. Issued: 12 Jan 1996; updated: Aug 2005. [accessed 2020 Oct]. https://www.canada.ca/en/health-canada/services/drugs-health-products/regulatory-requirements-advertising/policies-guidance-documents/policy-distinction-between-advertising-activities.html
   Google Scholar
• Food and Drug Administration. Guidance for industry: “Help-seeking” and other disease awareness communications by or on behalf of drug and device firms (draft guidance). January 2004 [accessed 2020 Oct]. https://www.hlregulation.com/files/2015/05/2004-draft-guidance-on-disease-awareness-activities.pdf
   Google Scholar
• Medicines and Healthcare products Regulatory Agency. Blue Guide, Advertising and promotion of medicines in the UK. Appendix 7: disease awareness campaign guidelines. Issued: Jul 2012; updated Nov 2020. [accessed 2020 Jul 2021]. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/956860/Appendix_7.pdf
   Google Scholar
• Advertising Standards Canada. DTCI guide. 2020 [accessed 2020 Oct]. https://adstandards.ca/wp-content/uploads/2020/02/DTCIGuideEN2020.pdf
   Google Scholar
• Medicines Australia. Code of conduct edition: 19. 2019 [accessed 2020 Nov]. https://www.medicinesaustralia.com.au/wp-content/uploads/2020/11/20200108-PUB-Edition-19-FINAL.pdf
   Google Scholar
• Israeli Ministry of Health, Pharmaceutical Administration. Guidance document #134. Disease awareness campaigns - rules for accessibility of information to the general public funded or sponsored by the MA holder or a third party. 2014 [Accessed 2020 Nov]. https://www.health.gov.il/hozer/DR_134.pdf
   Google Scholar
• Shani S. Prescription drugs communication to consumers in Israel - a new regulatory policy balancing between advertising and access to information. Med Law. 2016;35:25.
   Google Scholar
• Foundation for the Code for Pharmaceutical Advertising. Code of conduct for pharmaceutical advertising. 2019. [accessed 2021 Mar]. https://www.cgr.nl/CGR.nl/media/CGR.nl/Gedragscode/20190107-Dutch_CoC_Pharmaceutical_Advertising-ENG-per-20190701.pdf
   Google Scholar
• Association of the British Pharmaceutical Industry. ABPI 2021 code of practice. 2021 [accessed 2021 Apr]. https://www.abpi.org.uk/our-ethics/abpi-code-of-practice/#4e363de0
   Google Scholar
• Schwartz LM, Woloshin S. Medical marketing in the United States, 1997-2016. JAMA. 2019;321(1):80–96. doi:10.1001/jama.2018.19320.
   PubMed Web of Science ®Google Scholar
• Zaitsu M, Yoo B-K, Tomio J, Nakamura F, Toyokawa S, Kobayashi Y. Impact of a direct-to-consumer information campaign on prescription patterns for overactive bladder. BMC Health Serv Res. 2018;18:325. doi:10.1186/s12913-018-3147-1.
   PubMed Web of Science ®Google Scholar
• Hall DV, Jones SC, Iverson DC. Consumer perceptions of sponsors of disease awareness advertising. Health Educ. 2011;111(1):5–19. doi:10.1108/09654281111094946.
   Google Scholar
• Hall DV, Jones SC, Hoek J. Direct to consumer advertising versus disease awareness advertising: consumer perspectives from down under. J Public Affairs. 2011;11(1):60–69. doi:10.1002/pa.379.
   Google Scholar
• Kravitz RL, Epstein RM, Feldman MD, Franz CE, Azari R, Wilkes MS, Hinton L, Franks P. Influence of patients’ requests for direct-to-consumer advertised antidepressants: a randomized controlled trial. JAMA. 2005;293(16):1995–2002. doi:10.1001/jama.293.16.1995.
   PubMed Web of Science ®Google Scholar
• Doran E, Henry D. Disease mongering: expanding the boundaries of treatable disease. Intern Med J. 2008;38(11):858–61. doi:10.1111/j.1445-5994.2008.01814.x.
   PubMed Web of Science ®Google Scholar
• Schwartzberg E, Barnett-Itzhaki Z, Grotto I, Marom E. Strategies for patient empowerment through the promotion of medicines in Israel: regulatory framework for the pharmaceutical industry. Isr J Health Policy Res. 2017;6(1):50. doi:10.1186/s13584-017-0175-y.
   PubMedGoogle Scholar
• Mechler K, Rausch J, Mountford WK, Ries M. Disease awareness or subtle product placement? Orphan diseases featured in the television series “House, M.D.” - a cross-sectional analysis. BMC Med Ethics. 2020;21(1):20. doi:10.1186/s12910-020-0463-x.
   PubMed Web of Science ®Google Scholar
• Moynihan R, Heath I, Henry D. Selling sickness: the pharmaceutical industry and disease mongering. BMJ. 2002;324(7342):886–91. doi:10.1136/bmj.324.7342.886.
   PubMed Web of Science ®Google Scholar
• Mailankody S, Prasad V. Pharmaceutical marketing for rare diseases: regulating drug company promotion in an era of unprecedented advertisement. JAMA. 2017;317(24):2479–80. doi:10.1001/jama.2017.5784.
   PubMed Web of Science ®Google Scholar
• Mintzes B. Disease mongering in drug promotion: do governments have a regulatory role? PLoS Med. 2006;3(4):e198. doi:10.1371/journal.pmed.0030198.
   PubMed Web of Science ®Google Scholar
• Bélisle-Pipon J-C, Williams-Jones B. Preparing for the arrival of “pink Viagra”: strengthening Canadian direct-to-consumer information regulations. Can Med Assoc J. 2016;188(5):319. doi:10.1503/cmaj.150705.
   Web of Science ®Google Scholar
• Banerjee S, Dash SK. Effectiveness of disease awareness advertising in emerging economy: views of health care professionals of India. J Med Marketing. 2013;13(4):231–41. doi:10.1177/1745790413516479.
   Google Scholar
• The Editors. A public awareness campaign which mainly benefits companies. Prescrire Int. 2020;29(219):250.
   Google Scholar
• Sneyder Bulik B. Big pharma finds a hit with disease awareness social media posts in 2016. Fierce Pharma. 2017 [accessed 2021 Jul]. https://www.fiercepharma.com/marketing/big-pharma-social-media-savvy-rise-new-analysis-dishes-best-tweets-posts-and-engagement
   Google Scholar
• Quintanilha LF, Souza LN, Sanches D, Demarco RS, Fukutani KF. The impact of cancer campaigns in Brazil: a Google trends analysis. Ecancermedicalscience. 2019;13:963–963. doi:10.3332/ecancer.2019.963.
   PubMed Web of Science ®Google Scholar
• Hao Z, Liu M, Ge X. Evaluating the impact of health awareness events on Google search frequency. Preventive Med Rep. 2019;15:100887. doi:10.1016/j.pmedr.2019.100887.
   PubMedGoogle Scholar